Skip to main content
SpringerLink
Log in

Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy

  • Review
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Ovarian, fallopian tube and primary peritoneal carcinomas (OVCA) most commonly present in advanced stages and despite aggressive surgical resection and chemotherapy will likely recur. Although OVCA can recur in the liver, chest or brain, it most commonly recurs within the peritoneal cavity. Peritoneal spread is problematic and often results in bowel obstruction and the inability to maintain nutritional goals. Given the lethality of peritoneal disease as well as the difficulty in treating this recurrence pattern, novel tactics to treat peritoneal dissemination have been a focus of research in OVCA. Heated intraperitoneal chemotherapy (HIPEC) has been well studied and is utilized to treat appendiceal malignancies, which similarly involve the peritoneum. HIPEC has been shown to improve survival and decrease the risk of peritoneal recurrence in patients with appendiceal malignancies. This technique has also been shown to improve outcomes in patients with peritoneal metastases due to colorectal cancers and gastric cancers. Over the past three decades, HIPEC has been used to treat OVCA with mixed results. The aim of this paper is to review the use of HIPEC in the treatment of OVCA in the upfront and recurrent setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coalition WOC. The world ovarian cancer coalition atlas. https://docisolation.prod.fire.glass/?guid=902bb1c6-693d-4788-2497-b4a61115086d2018. Accessed 22 July 2019.

  2. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA A Cancer J Clin. 2018;68(4):284–96. https://doi.org/10.3322/caac.21456.

    Article  Google Scholar 

  3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. https://doi.org/10.1016/j.bpobgyn.2016.08.006.

    Article  PubMed  Google Scholar 

  4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. https://doi.org/10.1056/nejmoa052985.

    Article  CAS  PubMed  Google Scholar 

  5. Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33(26):2841–7. https://doi.org/10.1200/jco.2015.61.4776.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Giovanella BC, Stehlin JS Jr, Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 1976;36(11 Pt 1):3944–50.

    CAS  PubMed  Google Scholar 

  7. Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer (Oxford, England: 1990). 1991;27(4):472–7. https://doi.org/10.1016/0277-5379(91)90389-u.

    Article  CAS  Google Scholar 

  8. Los G, van Vugt MJ, den Engelse L, et al. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol. 1993;46(7):1229–37. https://doi.org/10.1016/0006-2952(93)90472-9.

    Article  CAS  PubMed  Google Scholar 

  9. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer. 1994;69(2):235–41. https://doi.org/10.1038/bjc.1994.45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer (Oxford, England: 1990). 2016;53:155–62. https://doi.org/10.1016/j.ejca.2015.09.017.

    Article  CAS  Google Scholar 

  11. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56. https://doi.org/10.1200/jco.2011.39.7166.

    Article  PubMed  Google Scholar 

  12. Faris JE, Ryan DP. Controversy and consensus on the management of patients with pseudomyxoma peritonei. Curr Treat Opt Oncol. 2013;14(3):365–73. https://doi.org/10.1007/s11864-013-0240-x.

    Article  Google Scholar 

  13. Mohamed F, Cecil T, Moran B, et al. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol (Toronto). 2011;18(2):e84–96. https://doi.org/10.3747/co.v18i2.663.

    Article  CAS  Google Scholar 

  14. Shaib WL, Martin LK, Choi M, et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. Oncologist. 2015;20(8):907–14. https://doi.org/10.1634/theoncologist.2014-0294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet (London). 2015;386(9990):249–57. https://doi.org/10.1016/s0140-6736(14)62223-6.

    Article  Google Scholar 

  16. Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–7. https://doi.org/10.1016/s1470-2045(18)30566-7.

    Article  PubMed  Google Scholar 

  17. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. https://doi.org/10.1056/NEJMoa0908806.

    Article  CAS  PubMed  Google Scholar 

  18. Chang SJ, Hodeib M, Chang J, et al. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130(3):493–8. https://doi.org/10.1016/j.ygyno.2013.05.040.

    Article  PubMed  Google Scholar 

  19. Narasimhulu DM, Khoury-Collado F, Chi DS. Radical surgery in ovarian cancer. Curr Oncol Rep. 2015;17(4):16. https://doi.org/10.1007/s11912-015-0439-z.

    Article  PubMed  Google Scholar 

  20. Ahmed S, Stewart JH, Shen P, et al. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol. 2014;110(5):575–84. https://doi.org/10.1002/jso.23749.

    Article  PubMed  Google Scholar 

  21. Amblard I, Mercier F, Bartlett DL, et al. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: a multi-institutional cohort from PSOGI and BIG RENAPE groups. Eur J Surg Oncol. 2018;44(9):1378–83. https://doi.org/10.1016/j.ejso.2018.04.023.

    Article  CAS  PubMed  Google Scholar 

  22. Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperth. 2017;33(5):562–70. https://doi.org/10.1080/02656736.2017.1283065.

    Article  Google Scholar 

  23. D’Hondt V, Goffin F, Roca L, et al. Interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first-line treatment for advanced ovarian carcinoma: a feasibility study. Int J Gynecol Cancer. 2016;26(5):912–7. https://doi.org/10.1097/igc.0000000000000696.

    Article  PubMed  Google Scholar 

  24. Di Giorgio A, De Iaco P, De Simone M, et al. Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases. Ann Surg Oncol. 2017;24(4):914–22. https://doi.org/10.1245/s10434-016-5686-1.

    Article  PubMed  Google Scholar 

  25. Gouy S, Ferron G, Glehen O, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–42. https://doi.org/10.1016/j.ygyno.2016.05.032.

    Article  CAS  PubMed  Google Scholar 

  26. Lee YJ, Lee JY, Cho MS, et al. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. J Gynecol Oncol. 2019;30(1):e3. https://doi.org/10.3802/jgo.2019.30.e3.

    Article  PubMed  Google Scholar 

  27. Lentz SS, Miller BE, Kucera GL, et al. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol. 2007;106(1):207–10. https://doi.org/10.1016/j.ygyno.2007.03.022.

    Article  CAS  PubMed  Google Scholar 

  28. Lim MC, Kang S, Choi J, et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol. 2009;16(4):993–1000. https://doi.org/10.1245/s10434-008-0299-y.

    Article  PubMed  Google Scholar 

  29. Paris I, Cianci S, Vizzielli G, et al. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Hyperth. 2018;35(1):370–4. https://doi.org/10.1080/02656736.2018.1503346.

    Article  CAS  Google Scholar 

  30. Pomel C, Ferron G, Lorimier G, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. J Surg Oncol. 2010;36(6):589–93. https://doi.org/10.1016/j.ejso.2010.04.005.

    Article  CAS  Google Scholar 

  31. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

    Article  PubMed  Google Scholar 

  32. Zivanovic O, Abramian A, Kullmann M, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136(3):699–708. https://doi.org/10.1002/ijc.29011.

    Article  CAS  PubMed  Google Scholar 

  33. Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43. https://doi.org/10.1016/j.ejso.2013.09.030.

    Article  CAS  PubMed  Google Scholar 

  34. Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19(13):4052–8. https://doi.org/10.1245/s10434-012-2510-4.

    Article  CAS  PubMed  Google Scholar 

  35. Cascales-Campos PA, Gil J, Feliciangeli E, et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015;22(3):987–93. https://doi.org/10.1245/s10434-014-4049-z.

    Article  PubMed  Google Scholar 

  36. Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19(7):2352–9. https://doi.org/10.1245/s10434-009-0878-6.

    Article  PubMed  Google Scholar 

  37. Classe JM, Glehen O, Decullier E, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res. 2015;35(9):4997–5005.

    CAS  PubMed  Google Scholar 

  38. Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case–control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502–5. https://doi.org/10.1016/j.ygyno.2012.09.020.

    Article  PubMed  Google Scholar 

  39. Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122(2):221–5. https://doi.org/10.1016/j.ygyno.2011.04.008.

    Article  PubMed  Google Scholar 

  40. Fagotti A, Paris I, Grimolizzi F, et al. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol. 2009;113(3):335–40. https://doi.org/10.1016/j.ygyno.2009.03.004.

    Article  CAS  PubMed  Google Scholar 

  41. Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5. https://doi.org/10.1245/s10434-014-4157-9.

    Article  CAS  PubMed  Google Scholar 

  42. van der Vange N, van Goethem AR, Zoetmulder FA, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol. 2000;26(7):663–8. https://doi.org/10.1053/ejso.2000.0978.

    Article  PubMed  Google Scholar 

  43. Petrillo M, De Iaco P, Cianci S, et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1660–5. https://doi.org/10.1245/s10434-015-5050-x.

    Article  CAS  PubMed  Google Scholar 

  44. Lim SL, Havrilesky LJ, Habib AS, et al. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019;153(2):376–80. https://doi.org/10.1016/j.ygyno.2019.01.025.

    Article  PubMed  Google Scholar 

  45. Koole SN, van Lieshout C, van Driel WJ, et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol. 2019;37(23):2041–50. https://doi.org/10.1200/jco.19.00594.

    Article  PubMed  Google Scholar 

  46. Wu J, Sun H, Yang L, et al. Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983–2012. J Cancer. 2018;9(19):3548–56. https://doi.org/10.7150/jca.26300.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth. 2017;33(5):582–92. https://doi.org/10.1080/02656736.2017.1291999.

    Article  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA

    Carrie Langstraat

Authors
  1. Carrie Langstraat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carrie Langstraat.

Ethics declarations

Conflict of interest

The author declares that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langstraat, C. Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Indian J Gynecol Oncolog 17, 94 (2019). https://doi.org/10.1007/s40944-019-0342-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-019-0342-x

Keywords

Search

Navigation